BioMarin Opens Office in Brisbane to Support Expanding Operations

NOVATO (Map) - NOVATO, Calif, Oct. 7 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has opened a new office in Brisbane, California, to expand its drug development operations and better meet the increasing demands of the company's growing product pipeline. The company will occupy approximately 20,000 square feet of office space located north of the San Francisco International Airport at 2000 Sierra Point Parkway, adjacent to Highway 101. The facility will house staff in biostatistics, statistical programming, clinical data management, medical writing and other clinical development functions. The new Brisbane office is part of a larger corporate expansion that has progressed throughout the past two years and includes the recent purchase of 300 Bel Marin Keys Boulevard in Novato. A multinational company, BioMarin Pharmaceutical operates offices in the United States, United Kingdom, Brazil and the Middle East, with employees in more than a dozen countries.

"With the rapid growth of our sales and product pipeline over the past four years, BioMarin has become one of the largest employers in the North Bay," said Mark Wood, BioMarin's Vice President of Human Resources. "The new office in Brisbane will help us sustain this growth and provide access to talent in the vibrant peninsula bio-pharma marketplace."

"BioMarin is making tremendous progress both domestically and internationally. With three drugs on the market and a rapidly growing product pipeline, we have accomplished a great deal in our short corporate history. We are very excited to further our expansion by opening new offices on the peninsula and adding much needed capacity to local operations in Novato," added

BioMarin opened its new Brisbane office on October 1, 2008 and has initiated targeted recruiting efforts for Brisbane-based positions. The company employs approximately 600 employees worldwide and has been recognized as one of the Bay Area's Best Places to Work for two years running.

For more information, please visit the BioMarin website at http://www.BMRN.com.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of PKU.

For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin(R), Naglazyme(R) and Kuvan(R) are a registered trademarks of BioMarin Pharmaceutical Inc.